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Abstract: A 67-year-old womanwas referred for staging of a mucosa-associated
lymphoid tumor lymphoma involving the left conjunctiva. CT scan had shown
paravertebral and pelvic masses, and a breast nodule. FDG PET/CT demon-
strated moderately increased uptake in the left ocular conjunctiva and confirmed
the paravertebral and pelvic masses and the breast nodule. Moreover, abnormal
FDG uptake was shown in 2 breast nodules, the flank, the gluteus maximus, and
the gastric cardia. The patient received 6 cycles of rituximab-bendamustine
chemotherapy with a complete clinical and metabolic response at the 6-month
follow-up PET/CT and remained relapse-free without visual acuity problem
after a 36-month follow-up.
Key Words: 18F, FDG, PET, ocular lymphoma, MALT, ocular adnexal
MALT lymphoma, conjunctival MALT lymphoma
(Clin Nucl Med 2014;39: 295Y297)
REFERENCES
1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-
Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic
locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998;9:
717Y720.
2. Thomas AG, Vaidhyanath R, Kirke R, et al. Extranodal lymphoma from head
to toe: part 1, the head and spine. AJR Am J Roentgenol. 2011;197:350Y356.
3. Matsuo T, Ichimura K, Tanaka T, et al. Conjunctival lymphoma can be detected
by FDG PET. Clin Nucl Med. 2012;37:516Y519.
4. Hayashi D, Devenney-Cakir B, Lee JC, et al. Mucosa-associated lymphoid
tissue lymphoma: multimodality imaging and histopathologic correlation. AJR
Am J Roentgenol. 2010;195:W105YW117.
5. Gayed I, Eskandari MF, McLaughlin P, et al. Value of positron emission to-
mography in staging ocular adnexal lymphomas and evaluating their response
to therapy. Ophthalmic Surg Lasers Imaging. 2007;38:319Y325.
6. Abdelmalik AG, Fajnwaks P, Osman MM, et al. Squamous cell carcinoma of
the bulbar conjunctiva seen on F-18 FDG PET/CT. Clin Nucl Med. 2010;35:
962Y964.
7. Lin LF, Chang CY, Cherng SC. Advanced squamous cell carcinoma of the
bulbar conjunctiva seen on PET/CT. Clin Nucl Med. 2008;33:929Y930.
8. Zanni M, Moulin-Romsee G, Servois V, et al. Value of 18FDG PET scan
in staging of ocular adnexal lymphomas: a large single-center experience.
Hematology. 2012;17:76Y84.
9. Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular
adnexa. Blood. 2009;114:501Y510.
10. Dabbagh Kakhki VR. 18F-FDG-PET, gallium-67 and somatostatin receptor
scintigraphy, in ocular MALT lymphoma. Hell J Nucl Med. 2008;11:49; author
reply 50.
INTERESTING IMAGE
Clinical Nuclear Medicine & Volume 39, Number 3, March 2014 www.nuclearmed.com 295
Received for publication July 8, 2013; revision accepted December 11, 2013.
From the Departments of *Nuclear Medicine, †Oncology, and ‡Hematology,
Lausanne University Hospital; §Jules Gonin Eye Hospital; ¶Department of
Pathology, Lausanne University Hospital, Lausanne; and ||Department of On-
cology, Sion Hospital, Sion, Switzerland.
Conflicts of interest and sources of funding: none declared.
Reprints: John O. Prior, PhD, MD, Department of Nuclear Medicine, Lausanne
University Hospital, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland.
E-mail:john.prior@chuv.ch.
This is an open-access article distributed under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible
to download and share thework provided it is properly cited. Thework cannot be
changed in any way or used commercially. http://creativecommons.org/licenses/
by-nc-nd/3.0.
Copyright * 2014 by Lippincott Williams & Wilkins
ISSN: 0363-9762/14/3903Y0295
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
FIGURE 1. A, Baseline FDG PET/CT showing increased glucose analog in the left conjunctiva (arrow) as compared with the
contralateral side (left-to-right SUV ratio, 3.0). B, Control after 3 of 6 cycles of chemotherapy showing an excellent metabolic
response with normalized left-to-right SUV ratio to 1.0 (arrowhead).
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FIGURE 2. A, Maximal intensity projection image of the baseline FDG PET showing extraocular lesions with increased pathologic
uptake situated in the right paravertebral mass (*), 3 left breast nodules (arrowhead), the gastric cardia (arrow), the left flank (f ),
the left gluteus maximus muscle (m), and a pelvic paramedian right mass (p). B, The same maximal intensity projection image
after 3 cycles of chemotherapy showing disappearance of all abnormal FDG uptake sites. The final diagnosis made on a biopsy of
the left conjunctiva was a marginal zone lymphoma of mucosa-associated lymphoid tumor (MALT) type (stage III EA). Extranodal
marginal zone lymphoma of MALT type is a relatively rare type of B-cell lymphoma accounting for 7% to 8% of non-Hodgkin
lymphomas.1 They arise in the stomach, bowel, lung, ocular adnexa, breast, thyroid, skin, soft tissue, and dura, predominantly in
patients older than 60 years.2 FDG PET/CT has now become part of the diagnostic workup of patients with lymphoma. It is known
as being more sensitive than CT for extranodal lesions usually upstaging the disease extent. PET is also now playing a role in the
follow-up of lymphoma and during the chemotherapy to assess initial response and determine prognosis. It is known that the
conjunctiva is one of the main sites of ocular lymphoma and that lymphomas of conjunctival origin can be detected by FDG PET/
CT.3Y5 Likewise, tumoral lesions of the bulbar conjunctiva of other origin can also be seen by FDG PET/CT.6,7 In the largest
up-to-date reported use of PET/CT in ocular adnexal lymphomas, Zanni et al8 reported 32% of conjunctival lymphomas with FDG
PET positivity in only 35% of the cases. In view of the high sensitivity of conventional imaging (CT/MRI) to detect conjunctival
involvement, FDG PET does not seem to be particularly useful for establishing the initial diagnosis, besides helping to choose the
biopsy site. However, FDG PET can be recommended for staging patients with ocular adnexal lymphomas because of the high
frequency of extraocular tumoral sites that can be multiple as in the case of our patient.3,8 FDG uptake is known to be lower or
negative in MALT lymphomas, although this has not been confirmed in ocular adnexal lymphomas.5 Nevertheless, scintigraphy
with somatostatin receptor analogs could be useful in selected cases.9,10 Indeed, the visualization of a unique lesion directly
influences the treatment strategy (surgery, radiation therapy) as compared with a disseminated disease (systemic therapy such as
single-agent or combination chemotherapy, immunotherapy with rituximab, monoclonal chimeric anti-CD20 antibodies, or
radioimmunotherapy with 90Y ibritumomab tiuxetan [Zevalin]; recently antichlamydial antibiotics therapy have also been
proposed as an alternative).9 The prognosis of MALT lymphoma of conjunctival origin is excellent, and the transformation into a
high-grade lymphoma is exceptional.
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